Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effort-based Decision-making and CPAP Adherence

NCT04557293 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2021-03-10
Last updated
2025-11-18

Condition(s) studied

Obstructive Sleep ApneaAdherence

Investigational drug(s) / intervention(s)

Continuous Positive Airway Pressure (CPAP) treatment

Continuous Positive Airway Pressure (CPAP) treatment: Treatment of Obstructive sleep apnoea syndrome with CPAP

Study summary

Obstructive sleep apnoea is the most common sleep disorder in general population, and is often associated with cognitive deficit, mood disorders, hypertension, diabetes mellitus, excessive daytime somnolence, nicturia and an increased cardiovascular and metabolic risk. The gold standard of treatment is Continuous Positive Airway Pressure (CPAP), but the adherence is often poor. The aim of our study is to investigate the effort based-decision making in patients with OSA, pre and post CPAP treatment, as a possible cause of poor adherence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 18 * AHI±15 Exclusion Criteria: * BMI ≥ 35 Kg/m2 * MMSE \<24 * Complex sleep apnoea * Sleep disorder * Psychiatric disorder

Primary outcome measure(s)

  • Memory — Change will be assesd before starting CPAP and after six months of CPAP treatment
    Short and Long-term memory will be assessed with Digit span and California verbal learning test
  • Executive Function — Change will be assesd before starting CPAPT and after six months of CPAP treatment
    attentional and executive functioning will be assessed with Test of Attentional Performance (TAP)
  • Planning — Change will be assesd before starting CPAPT and after six months of CPAP treatment
    Planning will be assessed with Tower of London
  • Response inhibition — Change will be assesd before starting CPAPT and after six months of CPAP treatment
    Will be assessed with Test Go-nogo
  • Efforth decision making — Change will be assesd before starting CPAPT and after six months of CPAP treatment
    Will be assesses with Rapid Serial Visual Presentation (RSVP)

Trial sites (1)

FacilityCityRegionStatus
ICS Maugeri Pavia Pavia Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04557293 on ClinicalTrials.gov ↗ ← All trials in Italy